Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Princess Margareth Cancer Center
Toronto, Ontario, Canada
Anna Spreafico, MD, PhDRecruiting
- Oxford University Hospital
Headington, Oxford, United Kingdom
Magdalena Kielak, MDMark Middleton, MD, FRCP (UK), PhDSimon Lord, MDRecruiting
- Next Oncology Dallas
Dallas, Texas, United States
Shiraj Sen, MD, PhDRecruiting - Next Oncology, San Antonio
San Antonio, Texas, United States
Anthony Tolcher, MD, FRCPC, FACP, FASCORecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Jul 2025
- Primary completion
- 31 Jan 2028
- Completion
- 31 Jan 2028
- Last update posted
- 29 Jan 2026
- Registered enrollment
- 110
- Registry id
- NCT07148128
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.